CO5390076A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
CO5390076A1
CO5390076A1 CO02092380A CO02092380A CO5390076A1 CO 5390076 A1 CO5390076 A1 CO 5390076A1 CO 02092380 A CO02092380 A CO 02092380A CO 02092380 A CO02092380 A CO 02092380A CO 5390076 A1 CO5390076 A1 CO 5390076A1
Authority
CO
Colombia
Prior art keywords
mycophenolic acid
mycophenolate
salt
tablet
amount
Prior art date
Application number
CO02092380A
Other languages
English (en)
Spanish (es)
Inventor
Jurgen Dederichs
Thomas Rigassi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5390076(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5390076A1 publication Critical patent/CO5390076A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
CO02092380A 2001-10-17 2002-10-15 Composiciones farmaceuticas CO5390076A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124953.1A GB0124953D0 (en) 2001-10-17 2001-10-17 Organic Compounds

Publications (1)

Publication Number Publication Date
CO5390076A1 true CO5390076A1 (es) 2004-04-30

Family

ID=9924043

Family Applications (1)

Application Number Title Priority Date Filing Date
CO02092380A CO5390076A1 (es) 2001-10-17 2002-10-15 Composiciones farmaceuticas

Country Status (31)

Country Link
US (3) US20050013859A1 (https=)
EP (1) EP1438040B2 (https=)
JP (2) JP2005508959A (https=)
KR (1) KR100671367B1 (https=)
CN (1) CN1310640C (https=)
AR (2) AR036813A1 (https=)
AT (1) ATE374023T1 (https=)
AU (1) AU2002338897B2 (https=)
BR (1) BR0213355A (https=)
CA (1) CA2460574A1 (https=)
CO (1) CO5390076A1 (https=)
CY (1) CY1107841T1 (https=)
DE (1) DE60222687T3 (https=)
DK (1) DK1438040T4 (https=)
EC (2) ECSP024342A (https=)
ES (1) ES2292819T5 (https=)
GB (1) GB0124953D0 (https=)
HU (1) HU231114B1 (https=)
IL (2) IL160968A0 (https=)
MX (1) MXPA04003636A (https=)
MY (1) MY139206A (https=)
NO (1) NO341804B1 (https=)
NZ (1) NZ532280A (https=)
PE (1) PE20030476A1 (https=)
PL (2) PL415001A1 (https=)
PT (1) PT1438040E (https=)
RU (2) RU2338528C2 (https=)
SI (1) SI1438040T2 (https=)
TW (1) TWI333861B (https=)
WO (1) WO2003032978A1 (https=)
ZA (1) ZA200401977B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
CA2623826A1 (en) * 2005-09-30 2007-04-12 Novartis Ag Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
ES2403167T3 (es) 2005-12-21 2013-05-14 Basf Se Polivinilpirrolidona entrelazada finamente dividida como agente desintegrador de tabletas
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
MX2009013063A (es) 2007-06-06 2010-01-15 Basf Se Formulacion farmaceutica para la produccion de tabletas de desintegracion rapida.
EP2164460B1 (de) 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
JP2011513391A (ja) * 2008-03-05 2011-04-28 パナセア バイオテック リミテッド ミコフェノラートを含有する徐放性医薬組成物およびその方法
EP2310008A4 (en) * 2008-07-09 2014-03-05 Aspreva Internat Ltd MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102793658A (zh) * 2012-08-23 2012-11-28 无锡福祈制药有限公司 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片
CN103845323B (zh) * 2012-11-30 2018-02-02 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
CN106727403A (zh) * 2017-01-03 2017-05-31 无锡福祈制药有限公司 一种麦考酚钠肠溶片及其制备方法
US11633378B2 (en) * 2017-03-13 2023-04-25 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) * 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
RU2723255C2 (ru) * 2018-11-14 2020-06-09 Общество с ограниченной ответственностью "Изварино Фарма" Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
AU2022214268A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
WO2022162409A1 (en) * 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators
US20240261218A1 (en) * 2021-05-26 2024-08-08 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN117442580B (zh) * 2023-12-21 2024-04-05 泊诺(天津)创新医药研究有限公司 一种高生物利用度麦考酚钠肠溶片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) † 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
JPS56127093A (en) * 1980-03-10 1981-10-05 Ajinomoto Co Inc Preparation of mycophenolic acid
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4748173A (en) * 1987-01-30 1988-05-31 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
AU3178293A (en) * 1992-11-24 1994-06-22 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
JP3725539B2 (ja) * 1993-02-26 2005-12-14 大正製薬株式会社 ビサコジル剤形
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
EP1475091A1 (en) * 1993-10-01 2004-11-10 Roche Palo Alto LLC Mycophenolate mofetil - high dose oral suspensions
JP3725542B2 (ja) * 1993-10-19 2005-12-14 大正製薬株式会社 ピコサルフェート剤形
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
DE60044717D1 (de) * 1999-05-10 2010-09-02 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
HUP9903226A2 (en) * 1999-09-23 2002-08-28 Gyogyszerki Process for producing mycophenolic acid and derivatives thereof
WO2001064931A1 (en) * 2000-02-29 2001-09-07 Biocon India Limited Manufacture and purification of mycophenolic acid
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1438040B2 (en) 2019-10-16
DE60222687D1 (de) 2007-11-08
US20050013859A1 (en) 2005-01-20
BR0213355A (pt) 2006-05-23
JP2005508959A (ja) 2005-04-07
HU231114B1 (hu) 2020-09-28
ECSP024342A (es) 2003-03-10
RU2381026C2 (ru) 2010-02-10
CA2460574A1 (en) 2003-04-24
US20100210717A1 (en) 2010-08-19
IL160968A0 (en) 2004-08-31
PL415001A1 (pl) 2016-02-29
ATE374023T1 (de) 2007-10-15
ES2292819T3 (es) 2008-03-16
CY1107841T1 (el) 2013-06-19
NZ532280A (en) 2007-05-31
WO2003032978A1 (en) 2003-04-24
PL234541B1 (pl) 2020-03-31
MY139206A (en) 2009-08-28
RU2004115332A (ru) 2005-04-20
HUP0600451A2 (en) 2006-09-28
GB0124953D0 (en) 2001-12-05
AR085778A2 (es) 2013-10-30
US20120237601A1 (en) 2012-09-20
ECSP024341A (es) 2003-12-01
JP2009137996A (ja) 2009-06-25
AU2002338897B2 (en) 2006-10-19
AR036813A1 (es) 2004-10-06
DE60222687T3 (de) 2020-03-05
TWI333861B (en) 2010-12-01
DK1438040T3 (da) 2008-02-04
CN1564684A (zh) 2005-01-12
DE60222687T2 (de) 2008-07-17
ES2292819T5 (es) 2020-05-29
PE20030476A1 (es) 2003-07-30
SI1438040T1 (sl) 2008-04-30
MXPA04003636A (es) 2004-07-27
PL367738A1 (en) 2005-03-07
IL160968A (en) 2016-04-21
NO341804B1 (no) 2018-01-22
ZA200401977B (en) 2006-05-31
EP1438040B1 (en) 2007-09-26
HK1067861A1 (en) 2005-04-22
KR20050037409A (ko) 2005-04-21
PT1438040E (pt) 2008-01-02
CN1310640C (zh) 2007-04-18
KR100671367B1 (ko) 2007-01-19
SI1438040T2 (sl) 2020-02-28
EP1438040A1 (en) 2004-07-21
RU2007130786A (ru) 2009-02-20
DK1438040T4 (da) 2020-01-27
NO20041785L (no) 2004-05-03
RU2338528C2 (ru) 2008-11-20

Similar Documents

Publication Publication Date Title
CO5390076A1 (es) Composiciones farmaceuticas
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
HRP20040996B1 (hr) Tablete visokog sadržaja lijeka
NO20043367L (no) Oralt farmasoytisk preparat
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
BRPI0413756A (pt) composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
BR0207880A (pt) Formulação farmacêutica, processo para preparação da mesma e uso de formulação sólida
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
UA41346C2 (uk) Фармацевтична композиція, яка містить флуоксетин або його сіль, таблетка на її основі, спосіб виробництва таблетки, яка диспергується
UA116334C2 (uk) Тверді форми дозування бендамустину
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
MX2024014628A (es) Compuesto para inhibir o degradar bcl6 y uso de este en farmacia
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
PA8580601A1 (es) Composicion farmaceutica de altas dosis
BR0114100A (pt) Formulações de liberação controlada para administração oral
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
CL2004000858A1 (es) Peptidos que comprende una region acida, una lipofilica o aromatica y una basica, que participan en transporte inverso de colesterol, composicion farmaceutica que los contienen, util para el tratamiento o prevencion de hipercolesterolemia y/o aterosc
CO5650230A2 (es) Composiciones estables de atorvastatina preparadas con granulacion en humedo
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.

Legal Events

Date Code Title Description
FC Application refused